Phase III, Single-arm, Open-label, International, Multi-centre Study to Evaluate the Efficacy and Safety of Lomitapide in Paediatric Patients with Homozygous Familial Hypercholesterolaemia (HoFH) on Stable Lipid-lowering Therapy

drug protocol number
APH-19
drug sponsor
Amryt Pharmaceuticals DAC
drug study
LOMITAPIDE
drug trial site
King Abdulaziz Medical City NG (Riyadh)
drug status
Ongoing
drug phase